Related Experiment Videos
Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy.
1Department of Neurology, Philipps University Marburg, Marburg, Germany.
Movement Disorders : Official Journal of the Movement Disorder Society
|December 19, 2001
Summary
Macrogol 3350 effectively treated constipation in patients with Parkinson's disease or multiple system atrophy. This open study showed significant symptom improvement in all ten participants.
Area of Science:
- Neurology
- Gastroenterology
Background:
- Constipation is a common and debilitating symptom in patients with neurodegenerative diseases like Parkinson's disease (PD) and multiple system atrophy (MSA).
- Effective management of constipation is crucial for improving the quality of life in these patients.
Purpose of the Study:
- To evaluate the efficacy of macrogol 3350 in treating constipation in patients diagnosed with Parkinson's disease or multiple system atrophy.
Main Methods:
- An open-label study was conducted involving 10 patients diagnosed with Parkinson's disease or multiple system atrophy experiencing constipation.
- Patients received treatment with macrogol 3350.
Main Results:
- Macrogol 3350 demonstrated a marked improvement in constipation symptoms across all ten participants.
- The treatment was well-tolerated, with no adverse events reported in this small cohort.
Conclusions:
- Macrogol 3350 is a promising therapeutic option for managing constipation in patients with Parkinson's disease and multiple system atrophy.
- Further large-scale, randomized controlled trials are warranted to confirm these findings.